Thursday, October 29, 2026
CN
  • About
  • Advertise
  • Careers
  • Contact
Money Compass
  • Home
  • Financial News
  • Investment News
  • Other News
    • Bursa News
    • Government News
    • Listing Companies News
    • Oversea Financial & Investment News
  • Interviews
    • Features Interviews
    • Corporate Interviews
  • Financial & Investment Articles
  • PR Newswire
  • Login
No Result
View All Result
Money Compass
Home PR Newswire

Asymchem Completes its First USFDA Pre-Approval Inspection (PAI) of the Tianjin 4 TIDES Manufacturing Site

Money Compass by Money Compass
October 29, 2026
in PR Newswire
0
Asymchem Completes its First USFDA Pre-Approval Inspection (PAI) of the Tianjin 4 TIDES Manufacturing Site
1
SHARES
102
VIEWS
Share on FacebookShare on Twitter

TIANJIN, China, Oct. 29, 2026 /PRNewswire/ — Asymchem successfully completed its first U.S. Food and Drug Administration (USFDA) Pre-Approval Inspection (PAI) of Asymchem Life Science (Tianjin) Co., Ltd.’s TIDES development and manufacturing facility (“TJ4”), which took place between June 29th to July 2nd, 2026.

Asymchem logo

Related posts

WSOT 2026 Is Live: Registration Opens for Bybit’s World Series of Trading, With a Prize Pool of Up to 10 Million USDT Across Crypto, Stocks, and AI

WSOT 2026 Is Live: Registration Opens for Bybit’s World Series of Trading, With a Prize Pool of Up to 10 Million USDT Across Crypto, Stocks, and AI

October 29, 2026
Ondo Intelligent Portfolios Lineup Expands to Solana

Ondo Intelligent Portfolios Lineup Expands to Solana

October 29, 2026

This marks the first western regulatory agency inspection of the Tianjin 4 site, which houses extensive modalities including peptides, oligonucleotides, drug product, payload linkers, excipients and small molecule API manufacturing capabilities. The PAI for a small molecule entity involved a comprehensive review of the site’s facility’s quality systems, data integrity measures, and manufacturing operations, and confirmed the rigorous quality structure in place.

“This milestone reflects the standards we hold ourselves to every day. Our systems, people and culture are built to deliver at the highest level, putting us in a position to successfully bring our valued partners through to commercialization.” stated Dr. Hao Hong, Chairman and CEO of Asymchem Group. 

The purpose-built TJ4 facility covering 41 acres integrates highly automated production for solid and liquid phase synthesis of both oligonucleotides and peptides, enzymatic ligation, prep-HPLC, TFF, as well as isolation capabilities including lyophilization, precipitation and spray drying capacity for both injectable and oral indications, with a fit-for-purpose design compliant with both NDA and BLA requirements. 

This FDA milestone reinforces Asymchem’s consistent regulatory performance, evidenced by roughly 200 annual global customer audits and over 100 regulatory inspections.

About Asymchem 

Founded in 1995, Asymchem is a leading global CDMO specializing in integrated solutions for the pharmaceutical and biotech sectors. With advanced R&D and manufacturing sites in China, the US, and Europe, Asymchem employs more than 10,000 professionals worldwide, delivers a broad range of services including small molecule, TIDES, biologics, synthetic biology, and more. The company’s ongoing investments in innovation and sustainability continue to drive value for its global client base.

For more information on Asymchem capabilities and capacities, visit www.asymchem.com 

SOURCE Asymchem Laboratories

​ 

Previous Post

NCS launches AI Mission Centre, commits to building a workforce of more than 300 Forward-Deployed Engineers in the next two years

Next Post

Haier Biomedical Brings Blood Management and Pharmaceutical Cold Storage Expertise to AABB and ISPE 2026

Next Post
Haier Biomedical Brings Blood Management and Pharmaceutical Cold Storage Expertise to AABB and ISPE 2026

Haier Biomedical Brings Blood Management and Pharmaceutical Cold Storage Expertise to AABB and ISPE 2026

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

BROWSE BY CATEGORIES

  • Blog
  • Bursa News
  • Corporate Interviews
  • Features Interviews
  • Financial & Investment Articles
  • Financial News
  • Government News
  • Investment News
  • Listing Companies News
  • Oversea Financial & Investment News
  • PR Newswire

BROWSE BY TOPICS

2018 League Balinese Culture Bali United Budget Travel business Champions League Chopper Bike Doctor Terawan industrial Istana Negara Malaysia Market Stories National Exam net zero emissions targets 2025 Renewable energy Visit Bali

Recent News

  • WSOT 2026 Is Live: Registration Opens for Bybit’s World Series of Trading, With a Prize Pool of Up to 10 Million USDT Across Crypto, Stocks, and AI
  • Ondo Intelligent Portfolios Lineup Expands to Solana
  • DEVELOPER CHARLES S. COHEN CLOSES FULL CONSTRUCTION FINANCING FOR WEST PALM POINT – WEST PALM BEACH’S NEWEST OFFICE TOWER

Category

  • Blog
  • Bursa News
  • Corporate Interviews
  • Features Interviews
  • Financial & Investment Articles
  • Financial News
  • Government News
  • Investment News
  • Listing Companies News
  • Oversea Financial & Investment News
  • PR Newswire
  • About
  • Advertise
  • Careers
  • Contact

Copyright © 2024 Money Compass Media (M) Sdn Bhd. All Rights Reserved

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Features Interviews
  • Government News
  • Financial News
  • Investment News
  • Listing Companies News
  • Corporate Interviews
  • Bursa News
  • Financial & Investment Articles
  • Oversea Financial & Investment News

Copyright © 2024 Money Compass Media (M) Sdn Bhd. All Rights Reserved